Tomorrow’s vector vaccines for small ruminants

Kyriakis, Constantinos S.

doi:10.1016/j.vetmic.2015.08.003

Cited by 9 publications

(5 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was contrary to observations where a 100X lower dose expressing the F protein of PPR showed complete protective immunity (123). The use of capripoxviruses as recombinant vectors has continued with proteins from numerous infectious viruses being expressed to provide full or partial protection against virulent challenge (124)(125)(126).…”

Section: Capripoxvirus As a Vectormentioning

confidence: 76%

Potential of Using Capripoxvirus Vectored Vaccines Against Arboviruses in Sheep, Goats, and Cattle

Teffera

Babiuk

2019

Front. Vet. Sci.

View full text Add to dashboard Cite

Capripoxviruses represent a genus of the poxviridae family under the subfamily chordopoxviriniae; the genus includes three animal virus species that have a devastating impact on sheep, goats, and cattle in Africa, Asia, and most recently Eastern Europe (1-4). The viruses in the genus are sheeppox virus (SPPV), goatpox virus (GTPV), and lumpy skin disease virus (LSDV) which affect sheep, goats, and cattle, respectively (1, 4). Capripoxviruses share 98% sequence similarity between

show abstract

Section: Capripoxvirus As a Vectormentioning

confidence: 76%

Potential of Using Capripoxvirus Vectored Vaccines Against Arboviruses in Sheep, Goats, and Cattle

Teffera

Babiuk

2019

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…Although it has been shown to induce Th1 and Th2 immune responses in BALB/c mice, it has not been evaluated in sheep or goats [ 48 ]. By promoting humoral and cellular immune responses, vaccines based on nucleic acids have been evaluated in small ruminants demonstrating promising results against bluetongue virus, rift valley fever virus, lentiviruses [ 51 ], Haemonchus contortus [ 52 ], and Toxoplasma gondii [ 53 ].…”

Section: Mycoplasma Agalactiae Vaccinesmentioning

confidence: 99%

Mycoplasma agalactiae Vaccines: Current Status, Hurdles, and Opportunities Due to Advances in Pathogenicity Studies

Barbosa,

Sampaio,

Spergser

et al. 2024

Vaccines

View full text Add to dashboard Cite

Contagious agalactia (CA) is a serious multietiological disease whose classic etiological agent is Mycoplasma agalactiae and which causes high morbidity and mortality rates in infected herds. CA is classified as a notifiable disease by the World Organization for Animal Health due to its significant worldwide economic impact on livestock, primarily involving goat and sheep farms. The emergence of atypical symptoms and strains of M. agalactiae in wildlife ungulates reestablishes its highly plastic genome and is also of great epidemiological significance. Antimicrobial therapy is the main form of control, although several factors, such as intrinsic antibiotic resistance and the selection of resistant strains, must be considered. Available vaccines are few and mostly inefficient. The virulence and pathogenicity mechanisms of M. agalactiae mainly rely on surface molecules that have direct contact with the host. Because of this, they are essential for the development of vaccines. This review highlights the currently available vaccines and their limitations and the development of new vaccine possibilities, especially considering the challenge of antigenic variation and dynamic genome in this microorganism.

show abstract

“…DNA vaccines act as PAMPs and cause humoral and cell-mediated reactions, which reduces the need for adjuvant (Mogensen 2009 ; Li et al. 2013 ; Kyriakis 2015 ). A strong MHC-I mediated CD8 + T cell response is induced by Plasmid-DNA and RNA vaccines (Sahin and Karikó 2014 ).…”

Section: Mastitis Immunotherapy and Other Strategiesmentioning

confidence: 99%

Immunotherapy in mastitis: state of knowledge, research gaps and way forward

Saleem,

Saleem Bhat,

A. Omonijo

et al. 2024

Veterinary Quarterly

View full text Add to dashboard Cite

Tomorrow’s vector vaccines for small ruminants

Cited by 9 publications

References 95 publications

Potential of Using Capripoxvirus Vectored Vaccines Against Arboviruses in Sheep, Goats, and Cattle

Potential of Using Capripoxvirus Vectored Vaccines Against Arboviruses in Sheep, Goats, and Cattle

Mycoplasma agalactiae Vaccines: Current Status, Hurdles, and Opportunities Due to Advances in Pathogenicity Studies

Immunotherapy in mastitis: state of knowledge, research gaps and way forward

Contact Info

Product

Resources

About